文献速递生殖医学

激素替代治疗周期冻融囊胚移植日低血清孕酮水平相关的临床因素

Clinical factors associated with low serum progesterone levels on the day of frozen blastocyst transfer in hormonal replacement therapy cycles.
PubMed 文献 · Hum Reprod · 2022-01-01

该观察性队列研究纳入2019年1月至2020年3月期间在一家三级大学医院接受激素替代治疗冻融胚胎移植的915例患者,分析移植日低血清孕酮(≤9.8 ng/ml)的相关因素。多因素分析显示BMI、产次、非欧洲地理来源和主动吸烟是独立相关因素;低孕酮组活产率较低(26.1% vs 33.2%,P=0.045),早期流产率较高(35.2% vs 21.5%,P=0.008)。

要点

  • 移植日血清孕酮≤9.8 ng/ml者占24.7%(226例)。
  • BMI(OR 1.06)、产次(OR 1.32)、非欧洲来源(OR 1.70)与低孕酮独立相关。
  • 主动吸烟与低孕酮独立负相关(OR 0.43)。

核心结论

  • BMI、产次和非欧洲地理来源是激素替代治疗周期冻融胚胎移植日低血清孕酮水平的独立相关因素,主动吸烟与低孕酮水平独立负相关。

研究设计与样本

  • 观察性队列研究,纳入2019年1月至2020年3月在一家三级大学医院接受激素替代治疗冻融胚胎移植的915例患者,每位患者仅纳入一次。
  • 子宫内膜准备采用外源性雌二醇和阴道微粒化孕酮,移植日晨在单一实验室检测血清孕酮。
  • 低血清孕酮定义为≤9.8 ng/ml(依据既往发表研究),采用单因素和多因素logistic回归分析相关因素。

主要发现

  • 226例(24.7%)患者移植日血清孕酮≤9.8 ng/ml。
  • 血清孕酮≤9.8 ng/ml组活产率26.1% vs 33.2%(P=0.045),早期流产率35.2% vs 21.5%(P=0.008)。
  • 单因素分析显示BMI(P<0.001)、产次(P=0.001)、非欧洲地理来源(P=0.001)、不孕持续时间(P=0.018)及口服雌二醇用于内膜准备(P=0.009)与低血清孕酮显著相关;低孕酮组主动吸烟者比例显著更低(P=0.002)。
  • 多因素分析显示BMI(OR 1.06,95%CI 1.02-1.11,P=0.002)、产次(OR 1.32,95%CI 1.04-1.66,P=0.022)、非欧洲地理来源(OR 1.70,95%CI 1.21-2.39,P=0.002)及主动吸烟(OR 0.43,95%CI 0.22-0.87,P=0.018)是与血清孕酮≤9.8 ng/ml相关的独立因素。

临床怎么用

  • 作者指出,低血清孕酮对激素替代治疗冻融胚胎移植结局的不良影响已被普遍认可,但导致患者间孕酮水平差异的因素尚待阐明,以帮助临床医生预测哪些患者亚组可从个体化孕酮补充中获益。

局限性

  • 主要局限性为观察性设计,存在选择和混杂偏倚风险,虽采用多因素分析以尽量减少该风险,但仍无法排除。
  • 将结果外推至其他实验室或其他孕酮给药途径和/或剂量也需验证。
  • 亟需未来研究探讨影响孕酮浓度的临床因素及潜在病理生理机制,以帮助临床医生预测哪些患者亚组可从个体化黄体期支持中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Which factors are associated with low serum progesterone (P) levels on the day of frozen embryo transfer (FET), in HRT cycles? SUMMARY ANSWER: BMI, parity and non-European geographic origin are factors associated with low serum P levels on the day of FET in HRT cycles. WHAT IS KNOWN ALREADY: The detrimental impact of low serum P concentrations on HRT-FET outcomes is commonly recognized. However, the factors accounting for P level disparities among patients receiving the same luteal phase support treatment remain to be elucidated, to help clinicians predicting which subgroups of patients would benefit from a tailored P supplementation. STUDY DESIGN, SIZE, DURATION: Observational cohort study with 915 patients undergoing HRT-FET at a tertiary care university hospital, between January 2019 and March 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients undergoing single autologous blastocyst FET under HRT using exogenous estradiol and vaginal micronized progesterone for endometrial preparation. Women were only included once during the study period. The serum progesterone level was measured in the morning of the FET, in a single laboratory. Independent factors associated with low serum P levels (defined as ≤9.8 ng/ml, according to a previous published study) were analyzed using univariate and multivariate logistic regression models. MAIN RESULTS AND THE ROLE OF CHANCE: Two hundred and twenty-six patients (24.7%) had a low serum P level, on the day of the FET. Patients with a serum P level ≤9.8 ng/ml had a lower live birth rate (26.1% vs 33.2%, P = 0.045) and a higher rate of early miscarriage (35.2% vs 21.5%, P = 0.008). Univariate analysis showed that BMI (P < 0.001), parity (P = 0.001), non-European geographic origin (P = 0.001), the duration of infertility (P = 0.018) and the use of oral estradiol for endometrial preparation (P = 0.009) were significantly associated with low serum P levels. Moreover, the proportion of active smokers was significantly lower in the 'low P concentrations' group (P = 0.002). After multivariate analysis, BMI (odds ratio (OR) 1.06 95% CI (1.02-1.11), P = 0.002), parity (OR 1.32 95% CI (1.04-1.66), P = 0.022), non-European geographic origin (OR 1.70 95% CI (1.21-2.39), P = 0.002) and active smoking (OR 0.43 95% CI (0.22-0.87), P = 0.018) remained independent factors associated with serum P levels ≤9.8 ng/ml. LIMITATIONS, REASONS FOR CAUTION: The main limitation of this study is its observational design, leading to a risk of selection and confusion bias that cannot be ruled out, although a multivariable analysis was performed to minimize this. WIDER IMPLICATIONS OF THE FINDINGS: Extrapolation of our results to other laboratories, or other routes and/or doses of administering progesterone also needs to be validated. There is urgent need for future research on clinical factors affecting P concentrations and the underlying pathophysiological mechanisms, to help clinicians in predicting which subgroups of patients would benefit from individualized luteal phase support. STUDY FUNDING/COMPETING INTEREST(S): No funding/no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Maignien C, Bourdon M, Marcellin L, et al. Clinical factors associated with low serum progesterone levels on the day of frozen blastocyst transfer in hormonal replacement therapy cycles. Hum Reprod. 2022. PMID: 36125015. doi:10.1093/humrep/deac199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。